undamentalytics Newsletter
Sign in

Ibio, Inc. revenue

Ibio, Inc.'s revenue was $100,000 in fiscal 2026, down 75.0% on the year before. Since fiscal 2011 ($520,080) it has grown at a compound -10.4% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Revenue5201,2771,0072051,8519483944442,0181,6382,3711,8840225400100
Growth on the year before—+145.5%−21.1%−79.6%+802.9%−48.8%−58.4%+12.7%+354.5%−18.8%+44.7%−20.5%−100.0%—+77.8%−75.0%
Gross profit—————————9359092,167————
Gross margin—————————57.1%38.3%—————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Ibio, Inc. $100,000 -75.0% -62.4%
Lisata Therapeutics, Inc. $100,000 -90.7% —
AIM Immunotech Inc. $95,000 -21.5% -17.3%
Celldex Therapeutics, Inc. $158,000 -97.3% -63.5%
Clene Inc. $197,000 -31.1% -36.9%
Cervomed Inc. $331,295 -95.7% -52.7%

Compare with peers

Head to head: IBIO vs LSTAAIM vs IBIOCLDX vs IBIOCLNN vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ibio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ibio, Inc.